Yuanqiong Duan
Overview
Explore the profile of Yuanqiong Duan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
63
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Duan Y, Wang Y, Lu S, Zeng M, Liu L, Dai Q, et al.
Front Pharmacol
. 2024 Nov;
15:1448144.
PMID: 39529884
Background: Abraxane plays a crucial role in the treatment of various types of cancer, despite the considerable attention it has garnered for its adverse drug events (ADEs). Nevertheless, there is...
2.
Zhong L, Wang W, Duan Y, Song L, Li Z, Yang K, et al.
Front Genet
. 2024 Oct;
15:1440179.
PMID: 39440242
Background: Lynch syndrome (LS) is an autosomal dominant inherited disorder caused by mutations in mismatch repair genes. Genetic counseling is crucial for the prevention and treatment of LS, as individuals...
3.
Zhou L, Duan Y, Fu K, Zhang M, Li K, Yin R
Front Immunol
. 2024 Sep;
15:1426050.
PMID: 39267740
Immunotherapy stands as a critical and auspicious therapeutic approach in the fight against cancer nowadays. Immune checkpoint inhibitors, in particular, have garnered widespread employment and delivered groundbreaking therapeutic outcomes across...
4.
Zeng J, Jiang W, Li K, Zhang M, Chen J, Duan Y, et al.
Front Oncol
. 2024 Jul;
14:1430742.
PMID: 39055567
Purpose: This study aimed to investigate the clinical and pathological characteristics, treatment strategies, and prognosis of cervical clear cell carcinoma (CCCC) in patients not exposed to diethylstilbestrol . Methods: The...
5.
Duan Y, Yang L, Wang W, Zhang P, Fu K, Li W, et al.
Front Pharmacol
. 2024 May;
15:1351363.
PMID: 38799160
Background: Despite extensive literature on therapeutic strategies for cervical cancer, a bibliometric analysis specifically focused on immunotherapy for advanced, recurrent, or metastatic (A/R/M) cervical malignancies remains unexplored. This study aims...
6.
Che M, Duan Y, Yin R
Front Oncol
. 2024 Apr;
14:1362673.
PMID: 38655134
Background: Radiotherapy, a primary treatment for malignant cancer, presents significant clinical challenges globally due to its associated adverse effects, especially with the increased survival rates of cancer patients. Radiation induced...
7.
Li W, Ma L, Li F, Li K, Zhang Y, Ren H, et al.
Radiat Oncol
. 2024 Apr;
19(1):46.
PMID: 38594678
Objective: To evaluate effects of bone marrow sparing (BMS) radiotherapy on decreasing the incidence of acute hematologic toxicity (HT) for locoregionally advanced cervical cancer (LACC) patients treated by pelvic irradiation....
8.
Chen J, Zhang M, Li K, Duan Y, Zeng J, Li Q, et al.
Front Oncol
. 2024 Feb;
14:1336616.
PMID: 38371630
Purpose: This study evaluated the efficacy and safety in a real-world population of epithelial ovarian cancer (EOC) treated with poly (ADP-ribose) polymerase inhibitor (PARPi) as first-line maintenance therapy in the...
9.
Chen J, Zhang M, Li K, Duan Y, Lin X, Zhong L, et al.
Front Oncol
. 2024 Jan;
13:1300199.
PMID: 38260846
Objective: The aim of this study is to assess the efficacy and safety of poly (ADP-ribose) polymerase inhibitor (PARPi) as a maintenance therapy for patients with platinum-sensitive recurrent epithelial ovarian...
10.
Duan Y, Gong Z, Wang W, Yin R
Asian J Surg
. 2023 Dec;
47(2):1314-1315.
PMID: 38072701
No abstract available.